UROwebinar: Standardised PSMA PET Analysis and Reporting Consensus (SPARC) and radioligand treatment in prostate cancer
This webinar aims to highlight the elements and rationale of the recent Standardised PSMA PET Analysis and Reporting Consensus (SPARC) initiative.
PSMA PET is playing an increasingly important role in the management of prostate cancer. However, there is a clear need for the standardised reading and reporting of PSMA PET to ensure information transfer from nuclear medicine to clinicians.
The Oncidium foundation is honored to be part of it by bringing two topics: the Patient's Perspective, presented by our US ambassador, Michael Crosby, a prostate cancer survivor whose PET Scan was crucial to receiving the right treatment, and the Reimbursement & Treatment Landscape, presented by our scientific director, Dr. Alice Viana.
Moderated by Dr. J. Walz, the agenda of the webinar is the following:
18:30 – 18:32
Introduction
J. Walz, Marseille (FR)
18:32 – 18:39
The elements and rational for SPARC
A.S. Bjartell, Malmö (SE)
18:39 – 18:49
Example cases of SPARC standards: detection & staging
K. Goffin, Leuven (BE)
18:49 – 18:59
Example cases of SPARC standards: BCR & treatment response
D. Oprea-Lager, Nijmegen (NL)
18:59 – 19:06
The PCWG4 and SPARC: These are the bridges
M. Morris, New York (US)
19:06 – 19:16
The landscape of radio ligand treatment in prostate cancer
J. Walz, Marseille (FR)
19:16 – 19:20
The Patient's Perspective
M. Crosby, San Diego (US)
19:20 – 19:24
Reimbursement and treatment landscape
A. Viana, Auderghem (BE)
19:24 – 19:40
Q&A
J. Walz, Marseille (FR)
This is the first time the foundation is collaborating with the official EAU webinars, and it marks an important step to bring urooncologists closer to Radioligand Therapy practices.
If you are a healthcare professional and would like to know more about Radiotheranostics, access our resources here!
We are looking for Urooncologists to be part of our ambassadors team and join us to spread the word about this therapy, so more patients can get access to it worldwide. Are you interested? Get in touch with us.
